)
)
Mineralys Therapeutics Investor Relations Material
Latest events
Q3 2024
Mineralys Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Mineralys Therapeutics Inc
Access all reports
Mineralys Therapeutics Inc. (MLYS) is a clinical-stage biopharmaceutical company developing treatments for diseases associated with abnormally elevated aldosterone levels. The company's flagship product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, currently under investigation for its potential in treating hypertension. The company is headquartered in Radnor, Pennsylvania, and its shares are listed on the Nasdaq.
Key slides for Mineralys Therapeutics Inc
Status Update
Mineralys Therapeutics Inc
Status Update
Mineralys Therapeutics Inc
Latest articles
)
Prada: The Story of an Icon
Prada's journey from a small Milan boutique to a global luxury empire, led by Miuccia's innovation and creativity.
5 Dec 2024
)
Hims & Hers: Bridging Gaps in Telehealth
Hims & Hers was founded in 2016 by Andrew Dudum and has grown into a ~$4 billion company in the telehealth industry in less than a decade.
5 Dec 2024
)
Andrew Dudum: Founder and CEO of Hims & Hers
Andrew Dudum is the founder and CEO of Hims & Hers, an innovative telehealth company focused on bridging the gap between consumers and healthcare.
4 Dec 2024
Ticker symbol
MLYS
Country
🇺🇸 United States